Marks Group Wealth Management Inc Purchases Shares of 29,879 Erasca, Inc. $ERAS

Marks Group Wealth Management Inc purchased a new position in shares of Erasca, Inc. (NASDAQ:ERAS) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 29,879 shares of the company’s stock, valued at approximately $483,000.

A number of other large investors also recently modified their holdings of ERAS. Spruce Street Capital LP purchased a new stake in shares of Erasca during the 4th quarter worth about $14,469,000. Vivo Capital LLC raised its holdings in Erasca by 37.2% in the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after buying an additional 2,516,672 shares during the period. State Street Corp lifted its position in Erasca by 53.2% during the fourth quarter. State Street Corp now owns 6,174,642 shares of the company’s stock valued at $22,970,000 after buying an additional 2,145,386 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in Erasca by 13.9% during the third quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company’s stock valued at $29,561,000 after buying an additional 1,652,835 shares in the last quarter. Finally, VR Adviser LLC lifted its position in Erasca by 10.1% during the second quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock valued at $22,678,000 after buying an additional 1,640,867 shares in the last quarter. 67.78% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Erasca said its updated preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue for KRAS-mutant cancers, support plans to move toward registration-enabling development, reinforcing the view that the drug could be a potentially best-in-class oncology asset. Article Title
• Positive Sentiment: The company also closed an upsized public offering, raising about $632.5 million in gross proceeds, which significantly strengthens its balance sheet and should help fund ongoing oncology development. Article Title
• Neutral Sentiment: One market note said the stock surged on encouraging cancer trial results, and another questioned whether the valuation has already run ahead of the fundamentals, suggesting investors are still debating how much upside the data justifies. Article Title
• Negative Sentiment: At the same time, multiple law firms issued class-action and deadline alerts over allegations that Erasca misled investors about ERAS-0015’s competitive position, safety profile, patent risk, and preclinical comparisons, keeping legal overhang front and center. Article Title
• Negative Sentiment: Those lawsuit updates likely add pressure because they reinforce concerns tied to the earlier patent-infringement dispute and a reported patient death after treatment with ERAS-0015, which had already triggered a sharp selloff earlier in the week. Article Title

Analyst Ratings Changes

Several research firms have recently issued reports on ERAS. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. HC Wainwright restated a “buy” rating on shares of Erasca in a report on Tuesday. Wall Street Zen cut shares of Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wolfe Research set a $16.00 price target on Erasca in a report on Thursday, June 4th. Finally, Stifel Nicolaus raised their price objective on Erasca from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.64.

Erasca Stock Down 10.5%

Shares of NASDAQ ERAS opened at $19.02 on Friday. The business has a 50 day moving average price of $14.37 and a two-hundred day moving average price of $13.33. Erasca, Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $24.28. The firm has a market cap of $5.91 billion, a PE ratio of -20.45 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last released its earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, analysts anticipate that Erasca, Inc. will post -0.55 earnings per share for the current year.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.